Basit öğe kaydını göster

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

dc.contributor.authorGravis, Gwenaelle
dc.contributor.authorTannock, Ian F.
dc.contributor.authorFizazi, Karim
dc.contributor.authorIvanov, Sergey
dc.contributor.authorKarlsson, Camilla Thellenberg
dc.contributor.authorFlechon, Aude
dc.contributor.authorSkoneczna, Iwona
dc.contributor.authorOrlandi, Francisco
dc.contributor.authorMatveev, Vsevolod
dc.contributor.authorBavbek, Sevil
dc.contributor.authorGil, Thierry
dc.contributor.authorViana, Luciano
dc.contributor.authorAren, Osvaldo
dc.contributor.authorKaryakin, Oleg
dc.contributor.authorElliott, Tony
dc.contributor.authorBirtle, Alison
dc.contributor.authorMagherini, Emmanuelle
dc.contributor.authorHatteville, Laurence
dc.contributor.authorPetrylak, Daniel
dc.contributor.authorTombal, Bertrand
dc.contributor.authorRosenthal, Mark
dc.date.accessioned2021-03-05T10:58:00Z
dc.date.available2021-03-05T10:58:00Z
dc.date.issued2013
dc.identifier.citationTannock I. F. , Fizazi K., Ivanov S., Karlsson C. T. , Flechon A., Skoneczna I., Orlandi F., Gravis G., Matveev V., Bavbek S., et al., "Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial", LANCET ONCOLOGY, cilt.14, ss.760-768, 2013
dc.identifier.issn1470-2045
dc.identifier.othervv_1032021
dc.identifier.otherav_a5d71981-64cb-4060-a00a-685b7c198916
dc.identifier.urihttp://hdl.handle.net/20.500.12627/110918
dc.identifier.urihttps://doi.org/10.1016/s1470-2045(13)70184-0
dc.description.abstractBackground Docetaxel plus prednisone is standard first-line chemotherapy for men with metastatic castrate-resistant prostate cancer. Aflibercept is a recombinant human fusion protein that binds A and B isoforms of VEGF and placental growth factor, thereby inhibiting angiogenesis. We assessed whether the addition of aflibercept to docetaxel and prednisone would improve overall survival in men with metastatic castrate-resistant prostate cancer compared with the addition of placebo to docetaxel and prednisone.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectOnkoloji
dc.titleAflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
dc.typeMakale
dc.relation.journalLANCET ONCOLOGY
dc.contributor.departmentUniversity Of Toronto , ,
dc.identifier.volume14
dc.identifier.issue8
dc.identifier.startpage760
dc.identifier.endpage768
dc.contributor.firstauthorID210136


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster